163521-08-2 | Vilazodone hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$30.00	$21.00
1g	98%	in stock	$69.00	$48.00
5g	98%	in stock	$229.00	$160.00

Description

• Catalog Number: AA85592
• Chemical Name: Vilazodone hydrochloride
• CAS Number: 163521-08-2
• Molecular Formula: C26H28ClN5O2
• Molecular Weight: 477.9858
• MDL Number: MFCD00940014
• SMILES: N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2.Cl

Computed Properties

• Complexity: 729
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7

Literature

• A review of current evidence for vilazodone in major depressive disorder.

  International journal of psychiatry in clinical practice 20130801

• Evidence for the use of vilazodone in the treatment of major depressive disorder.

  Expert opinion on pharmacotherapy 20121001

• Vilazodone for the treatment of major depressive disorder.

  Pharmacotherapy 20121001

• Vilazodone's comparative merits yet to be demonstrated.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120915

• Vilazodone: a novel antidepressant.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120915

• Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  International journal of clinical practice 20120401

• New drugs 2012 part I.

  Nursing 20120301

• The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.

  Current medical research and opinion 20120101

• Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.

  Current medicinal chemistry 20120101

• A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.

  Journal of clinical psychopharmacology 20111001

• Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.

  The Journal of clinical psychiatry 20110901

• A new antidepressant.

  Behavioral healthcare 20110901

• Vilazodone (Viibryd)--a new antidepressant.

  The Medical letter on drugs and therapeutics 20110711

• Vilazodone for the treatment of depression.

  The Annals of pharmacotherapy 20110701

• Vilazodone: in major depressive disorder.

  CNS drugs 20110701

• Vilazodone: a new treatment option for major depressive disorder.

  Drugs of today (Barcelona, Spain : 1998) 20110701

• A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.

  The Journal of clinical psychiatry 20110401

• Vilazodone: another novel atypical antidepressant drug.

  Journal of psychosocial nursing and mental health services 20110301

• Vilazodone approved for major depression.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110301

• Vilazodone hydrochloride, linagliptin, and alcaftadine.

  Journal of the American Pharmacists Association : JAPhA 20110101

• Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.

  Expert opinion on investigational drugs 20091101

• Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

  The Journal of clinical psychiatry 20090301

• Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

  CNS neuroscience & therapeutics 20090101

• Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.

  IDrugs : the investigational drugs journal 20070301

• Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.

  European journal of pharmacology 20050704

• Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

  European journal of pharmacology 20050307

• Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats.

  European journal of pharmacology 20041103

• Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.

  Bioorganic & medicinal chemistry 20040915

• A new synthesis of indole 5-carboxylic acids and 6-hydroxy-indole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone.

  Bioorganic & medicinal chemistry letters 20040517

• Phase I and II enzyme characterization of two sources of HepG2 cell lines.

  Xenobiotica; the fate of foreign compounds in biological systems 20040301

• Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.

  The Journal of pharmacology and experimental therapeutics 20020901

• Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.

  Psychopharmacology 20010501

• Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test.

  European journal of pharmacology 20010302